Skip to main content
SpringerLink
Log in

The spectrum of multiple sclerosis

  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

Abstract

Multiple sclerosis (MS) is the most common cause of chronic neurologic disability in young people. Genetic susceptibility and unidentified environmental triggers appear to be necessary in order to result in disease. MS is an extraordinarily complex trait with evidence of heterogeneity at clinical, pathologic, and therapeutic levels. Recent studies have not resolved the important question whether at a mechanistic level MS is a single disease with a wide spectrum of clinical expression, or whether it encompasses a group of separate diseases that share certain pathologic final common pathways. This question is important not only for helping to understand the causes of MS but also for designing and applying better treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Compston A, ed: McAlpine’s Multiple Sclerosis, edn 4. New York: Churchill Livingston, 2005.

    Google Scholar 

  2. Lublin FD, Reingold SC: Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996, 46:907–911.

    PubMed  CAS  Google Scholar 

  3. Weinshenker BG, Bass B, Rice GP, et al.: The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989, 112:133–146.

    Article  PubMed  Google Scholar 

  4. Tullman MJ, Oshinsky RJ, Lublin FD, Cutter GR: Clinical characteristics of progressive relapsing multiple sclerosis. Mult Scler 2004, 10:451–454.

    Article  PubMed  CAS  Google Scholar 

  5. Korteweg T, Tintore M, Uitdehaag B, et al.: MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurol 2006, 5:221–227.

    Article  PubMed  Google Scholar 

  6. Wilejito M, Shroff M, Buncic JR, et al.: The clinical features, MRI findings and outcome of optic neuritis in children. Neurology 2006, 67:258–262.

    Article  Google Scholar 

  7. Tremlett H, Devonshire V: Is late-onset multiple sclerosis associated with a worse outcome? Neurology 2006, 67:954–959.

    Article  PubMed  Google Scholar 

  8. De Stefano N, Cocco E, Lai M, et al.: Imaging brain damage in first-degree relatives of sporadic and familial multiple sclerosis. Ann Neurol 2006, 59:634–639.

    Article  PubMed  Google Scholar 

  9. Wingerchuk DM, Lennon VA, Pittock SJ, et al.: Revised dignostic criteria for neuromyelitis optica. Neurology 2006, 66:1485–1489.

    Article  PubMed  CAS  Google Scholar 

  10. Rubio JP, Bahlo M, Butzkueven H, et al.: Genetic dissection of the human leukocyte antigen region by use of haplotypes of Tasmanians with multiple sclerosis. Am J Hum Gen 2002, 70:1125–1137.

    Article  CAS  Google Scholar 

  11. Lincoln MR, Montpetit A, Cader MZ, et al.: A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet 2005, 37:1108–1112.

    Article  PubMed  CAS  Google Scholar 

  12. Giovannoni G, Cutter GR: Infectious causes of multiple sclerosis: contemporary criteria for causation in multiple sclerosis. Lancet Neurol 2006, 5:887–894.

    Article  PubMed  Google Scholar 

  13. Brosnan CF, Raine CS: Mechanisms of immune injury in multiple sclerosis. Brain Pathol 1996, 6:243–257.

    PubMed  CAS  Google Scholar 

  14. Barnett MH, Sutton I: The pathology of multiple sclerosis: a paradigm shift. Curr Opin Neurol 2006, 19:242–247.

    Article  PubMed  Google Scholar 

  15. Bruck W, Kuhlmann T, Stadelmann C: Remyelination in multiple sclerosis. J Neurol Sci 2003, 206:181–185.

    Article  PubMed  Google Scholar 

  16. Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H: Distinct patterns of multiple sclerosis pathology indicate heterogeneity on pathogenesis. Brain Pathol 1996, 6:259–274.

    PubMed  CAS  Google Scholar 

  17. Lucchinetti C, Bruck W, Parisi J, et al.: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000, 47:707–717.

    Article  PubMed  CAS  Google Scholar 

  18. Barnett MH, Prineas JW: Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004, 55:458–468.

    Article  PubMed  Google Scholar 

  19. Lennon VA, Kryzer TJ, Pittock SJ, et al.: IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005, 202:473–477.

    Article  PubMed  CAS  Google Scholar 

  20. Weinshenker BG, Wingerchuk DM, Vukusic S, et al.: Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006, 59:566–569.

    Article  PubMed  CAS  Google Scholar 

  21. Reindl M, Khalil M, Berger T: Antibodies as biological markers for pathophysiological processes in MS. J Neuroimmunol 2006, 180:50–62.

    Article  PubMed  CAS  Google Scholar 

  22. Jurewicz A, Matysiak M, Raine CS, Selmaj K: Soluble Nogo-A, an inhibitor of axonal regeneration, as a biomarker for multiple sclerosis. Neurology 2007, 68:283–287.

    Article  PubMed  CAS  Google Scholar 

  23. Confavreux C, Vukusic S: Natural history of multiple sclerosis: a unifying concept. Brain 2006, 129:606–616.

    Article  PubMed  Google Scholar 

  24. Coles AJ, Wing MG, Molyneux P, et al.: Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999, 46:296–304.

    Article  PubMed  CAS  Google Scholar 

  25. Haegert DG: Clinical multiple sclerosis occurs at one end of a spectrum of CNS pathology: a modified threshold liability model leads to new ways of thinking about the cause of clinical multiple sclerosis. Med Hypotheses 2005, 65:232–237.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Immunology, Westmead Hospital, Westmead, NSW, 2145, Australia

    Robert N. S. Heard MD, FRCP, FRACP

Authors
  1. Robert N. S. Heard MD, FRCP, FRACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert N. S. Heard MD, FRCP, FRACP.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heard, R.N.S. The spectrum of multiple sclerosis. Curr Allergy Asthma Rep 7, 280–284 (2007). https://doi.org/10.1007/s11882-007-0042-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11882-007-0042-y

Keywords

Search

Navigation